August 13, 2019
Milestone Pharmaceuticals posts operating loss of $13.7 in Q2, 2109, advances pivotal etripamil program
Milestone Pharmaceuticals gets to advance its pivotal program of etripamil, its novel, potent and short-acting calcium channel blocker, in patients with paroxysmal supraventricular tachycardia (PSVT), the company said in an quarter and half year financial update.